Clinical Trial Update: Post Marketing Surveillance Study of Biphasic Insulin Aspart 30

View source ↗

Summary

A post-marketing surveillance study of Biphasic Insulin Aspart 30 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Biphasic insulin aspart 30 (insulin aspart, biphasic 30/70)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Status: COMPLETED